Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Michael Ohr
New York, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Ohr Pharmaceutical developed squalamine eye drops for wet AMD and other retinal diseases but failed to meet primary endpoints in pivotal trials. The company merged with NeuBase Therapeutics in 2019 to focus on rare genetic diseases using a novel peptide-nucleic acid antisense platform targeting severe neurological disorders such as Huntington's disease and myotonic dystrophy. The merged entity planned IND filings starting in 2020.
- Therapeutic areas
- OncologyRare DiseasesOphthalmologyNeurology
- Modalities
- Small moleculePeptide-nucleic acid antisense oligonucleotide
- Industry
- Biotech
02
Partnerships
Strategic partnership via merger with NeuBase Therapeutics
Beyond the preview
Go deeper on Michael Ohr.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Michael Ohr.